NASDAQ:TECX Tectonic Therapeutic (TECX) Stock Price, News & Analysis $21.04 +0.96 (+4.78%) Closing price 04:00 PM EasternExtended Trading$21.44 +0.40 (+1.90%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tectonic Therapeutic Stock (NASDAQ:TECX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tectonic Therapeutic alerts:Sign Up Key Stats Today's Range$20.08▼$21.3450-Day Range$18.98▼$30.4852-Week Range$16.77▼$39.53Volume169,435 shsAverage Volume252,951 shsMarket Capitalization$419.75 millionP/E RatioN/ADividend YieldN/APrice Target$69.17Consensus RatingModerate Buy Company Overview Tectonic Therapeutic is a biotechnology company developing biologic medicines that target G protein-coupled receptors (GPCRs), a broad class of proteins involved in many biological processes. Its GEODe platform is designed to identify and engineer antibodies and other biologics that act on GPCRs. The company’s lead clinical program, TX000045, is an antibody designed to activate the apelin receptor. Tectonic is developing it for pulmonary arterial hypertension, a serious condition affecting the blood vessels in the lungs. Founded in 2019, Tectonic was launched with backing from Third Rock Ventures. The company is based in Massachusetts and is led by Chief Executive Officer Paul Grayson.AI Generated. May Contain Errors. Read More Tectonic Therapeutic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreTECX MarketRank™: 2.758506113765 of 5 starsTectonic Therapeutic scored higher than 55% of companies evaluated by MarketBeat, and ranked 425th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingTectonic Therapeutic has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTectonic Therapeutic has a consensus price target of $69.17, representing about 228.0% upside from its current price of $21.09.Amount of Analyst CoverageTectonic Therapeutic has only been the subject of 4 research reports in the past 90 days.Read more about Tectonic Therapeutic's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tectonic Therapeutic are expected to decrease in the coming year, from ($4.89) to ($5.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tectonic Therapeutic is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tectonic Therapeutic is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTectonic Therapeutic has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.19% of the float of Tectonic Therapeutic has been sold short.Short Interest Ratio / Days to CoverTectonic Therapeutic has a short interest ratio ("days to cover") of 13.66, which indicates bearish sentiment.Change versus previous monthShort interest in Tectonic Therapeutic has recently increased by 6.79%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTectonic Therapeutic does not currently pay a dividend.Dividend GrowthTectonic Therapeutic does not have a long track record of dividend growth. News and Social Media4.0 / 5News SentimentN/A News SentimentTectonic Therapeutic has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tectonic Therapeutic this week, compared to 1 article on an average week.Search Interest2 people have searched for TECX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Tectonic Therapeutic to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tectonic Therapeutic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,920.00 in company stock.Percentage Held by Insiders39.80% of the stock of Tectonic Therapeutic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.63% of the stock of Tectonic Therapeutic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tectonic Therapeutic's insider trading history. Receive TECX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tectonic Therapeutic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TECX Stock News HeadlinesTectonic Therapeutic to Participate in Upcoming Investor ConferencesNovember 9, 2026 | globenewswire.comTectonic Therapeutic (NASDAQ:TECX) Stock Rating Upgraded by Wall Street ZenNovember 7, 2026 | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 18 at 1:00 AM | Weiss Ratings (Ad)Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 6, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX), Boston Scientific (BSX) and Liquidia Technologies (LQDA)October 15, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Solid Biosciences (SLDB)October 1, 2026 | theglobeandmail.comTectonic Therapeutic Says TX2100 Phase 1a Trial Met Primary ObjectivesSeptember 29, 2026 | finance.yahoo.comTectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)September 29, 2026 | globenewswire.comSee More Headlines TECX Stock Analysis - Frequently Asked Questions How have TECX shares performed this year? Tectonic Therapeutic's stock was trading at $20.86 at the beginning of 2026. Since then, TECX stock has increased by 1.1% and is now trading at $21.0880. How were Tectonic Therapeutic's earnings last quarter? Tectonic Therapeutic, Inc. (NASDAQ:TECX) released its earnings results on Thursday, November, 5th. The company reported ($1.08) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.24. When did Tectonic Therapeutic IPO? Tectonic Therapeutic (TECX) raised $89 million in an IPO on Thursday, June 21st 2018. The company issued 5,247,958 shares at $16.00-$18.00 per share. Who are Tectonic Therapeutic's major shareholders? Top institutional investors of Tectonic Therapeutic include Marshall Wace LLP (2.24%), State Street Corp (1.11%), Aberdeen Group plc (0.96%) and Goldman Sachs Group Inc. (0.92%). Insiders that own company stock include Timothy A Springer, Marcella K Ruddy, Peter Mcnamara and Daniel Lochner. View institutional ownership trends. How do I buy shares of Tectonic Therapeutic? Shares of TECX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/05/2026Today11/18/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TECX's financial health is in the Yellow zone, according to TradeSmith. TECX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TECX Previous SymbolNASDAQ:TECX CIK1681087 Webwww.tectonictx.com Phone617-914-8420FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Tectonic Therapeutic$69.17 High Price Target$93.00 Low Price Target$26.00 Potential Upside/Downside+228.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.69% Return on Assets-35.65% Debt Debt-to-Equity RatioN/A Current Ratio19.71 Quick Ratio19.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.50 per share Price / Book1.83Miscellaneous Outstanding Shares19,950,000Free Float12,009,000Market Cap$419.75 million OptionableOptionable Beta3.51 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:TECX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.